News Related to Moleculin Biotech, Inc.

Related coverage linked through entity extraction aliases.

Moleculin Reports 40% Response Rate in Pivotal AML Trial, Unblinding Expected Q1 2026

Feb 18, 2026

Moleculin Biotech announced a preliminary blinded composite complete remission rate of 40% in the first 30 subjects of its Phase 2B/3 MIRACLE trial testing Annamycin plus cytarabine for relapsed or refractory acute myeloid leukemia.

Moleculin Receives Japanese Patent Allowance for Annamycin Preparation Methods

Feb 17, 2026

Moleculin Biotech announced the Japan Patent Office has issued a notice of allowance for a patent covering proprietary methods for reconstituting liposomal Annamycin, strengthening the company's international intellectual property position.